EUVIMEDEUVIMED entdecken
Leserbrief

Effect of the Presence of t(11;14) for Patients With AL Amyloidosis Treated With Bortezomib-Containing Regimens: Experience From the Amyloidosis Program of Calgary

Ellen Lewis, Sylvia McCulloch, Etienne Mahe, Nizar Bahlis, Paola Neri, Jason Tay, Peter Duggan, Victor H Jimenez-Zepeda

Clinical Lymphoma Myeloma and Leukemia · 2023

DOI: 10.1016/j.clml.2023.07.004 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2023. Verfasst von Ellen Lewis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Hematology, Tom Baker Cancer Centre/University of Calgary, Calgary, AB, Canada. Hauptthemen laut MEDLINE: Immunoglobulin Light-chain Amyloidosis, Amyloidosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulin Light-chain AmyloidosisAmyloidosisHumansBortezomibBoronic AcidsDexamethasoneTreatment Outcome

Substanzen

BortezomibBoronic AcidsDexamethasone

Autor:innen und Institutionen

  • Department of Medical Oncology and Hematology, Tom Baker Cancer Centre/University of Calgary, Calgary, AB, Canada.
  • Department of Medical Oncology and Hematology, Tom Baker Cancer Centre/University of Calgary, Calgary, AB, Canada; Department of Pathology and Lab Medicine, Department of Medicine, University of Calgary, Calgary, AB, Ca…
  • Department of Medical Oncology and Hematology, Tom Baker Cancer Centre/University of Calgary, Calgary, AB, Canada; Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada.
  • Department of Medical Oncology and Hematology, Tom Baker Cancer Centre/University of Calgary, Calgary, AB, Canada; Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada. Electronic addr…

Zitieren

APA

Lewis, E., McCulloch, S., Mahe, E., Bahlis, N., Neri, P., Tay, J., Duggan, P., & Jimenez-Zepeda, V. H. (2023). Effect of the Presence of t(11;14) for Patients With AL Amyloidosis Treated With Bortezomib-Containing Regimens: Experience From the Amyloidosis Program of Calgary. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2023.07.004

Vancouver

Lewis E, McCulloch S, Mahe E, Bahlis N, Neri P, Tay J, et al. Effect of the Presence of t(11;14) for Patients With AL Amyloidosis Treated With Bortezomib-Containing Regimens: Experience From the Amyloidosis Program of Calgary. Clinical Lymphoma Myeloma and Leukemia. 2023. doi:10.1016/j.clml.2023.07.004

BibTeX
@article{Lewis2023,
  author = {Lewis, Ellen and McCulloch, Sylvia and Mahe, Etienne and Bahlis, Nizar and Neri, Paola and Tay, Jason and Duggan, Peter and Jimenez-Zepeda, Victor H},
  title = {Effect of the Presence of t(11;14) for Patients With AL Amyloidosis Treated With Bortezomib-Containing Regimens: Experience From the Amyloidosis Program of Calgary},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2023},
  doi = {10.1016/j.clml.2023.07.004}
}
Kostenlos starten →